Fig. 3: PLK1 inhibition potentiates PD-L1 blockade in syngeneic lung tumors.
From: Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
a C57BL/6 mice were injected with 200,000 LLC-JSP cells on the right flank. On day 0 (8 post tumor inoculation), mice were grouped (n = 7–8) and received i.p. treatments of control vehicles (PBS and HCl/saline), PLK1 inhibitor volasertib (20 mg/kg), PD-L1 antibody (10 mg/kg), or combination of PLK1 inhibitor and PD-L1 antibody at the same dose. Treatments were administered every 5 days for 3 doses. b Tumor growth of mice. Data presented as mean ± SEM; ****P < 0.0001 (mixed model Two-Way repeated measures ANOVA with Tukey’s correction for multiple comparisons). c Kaplan–Meier Survival curve. ***P = 0.0007 vs. saline (Log-rank Mantel–Cox test). Source data are provided as a Source Data file.
